Life expectancy is significantly reduced in people with type 1 diabetes, and quality of life is frequently affected by eye, kidney, foot, and cardiovascular disease. Achieving and sustaining control of blood glucose to reduce the risk of these complications is a substantial challenge for many affected individuals. One strategy under investigation is the repurposing of drugs used in other conditions as adjunct therapy.¹ An ideal adjunct agent—added to insulin therapy—would provide a sustained reduction in blood glucose concentrations without increasing hypoglycaemia, while preventing insulin-induced weight gain and improving cardiovascular outcomes.

中文翻译：

---

SGLT2抑制剂在1型糖尿病中的作用：下降但又上升？

1型糖尿病患者的预期寿命显着降低，并且生活质量经常受到眼，肾，足和心血管疾病的影响。对于许多受影响的个体而言，实现并维持血糖控制以降低发生这些并发症的风险是一项重大挑战。正在研究的一种策略是将在其他情况下使用的药物作为辅助疗法进行再利用。¹一种理想的辅助剂（添加到胰岛素治疗中）可在不增加低血糖的情况下持续降低血糖浓度，同时防止胰岛素引起的体重增加并改善心血管结局。